NASDAQ: GOSSGossamer Bio Inc Stock
$0.17+0.00 (+0%)
Updated Jun 16, 2026
GOSS Price
$0.17
Fair Value Price
$0.10
Market Cap
$39.43M
52 Week Low
$0.14
52 Week High
$3.87
P/E
-0.21x
P/B
-0.24x
P/S
1.39x
PEG
N/A
Dividend Yield
N/A
Revenue
$55.54M
Earnings
-$180.40M
Gross Margin
100%
Operating Margin
-305.18%
Profit Margin
-324.8%
Debt to Equity
-1.8
Operating Cash Flow
-$170M
Beta
1.46
Next Earnings
Aug 4, 2026
Ex-Dividend
N/A
Next Dividend
N/A
GOSS Overview
Gossamer Bio, Inc. operates as a U.S.-based, clinical-stage biopharmaceutical company. Its primary objective is to discover, acquire, advance, and market novel therapeutic solutions, specifically addressing conditions within immunology, inflammatory diseases, and oncology. The company's pipeline highlights several key drug candidates: GB002: An inhaled small molecule designed to inhibit platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT, currently being developed for pulmonary arterial hypertension. GB004: An oral, gut-targeted small molecule in development for treating inflammatory bowel disease. GB5121: An oral, irreversible covalent small molecule that targets Bruton's Tyrosine Kinase (BTK), intended for primary central nervous system lymphoma. GB7208: Another oral small molecule BTK inhibitor, under investigation for multiple sclerosis. To support its drug development initiatives, Gossamer Bio has forged strategic licensing partnerships. It holds agreements with Pulmokine, Inc. for the advancement and commercialization of GB002 and its associated backup compounds. Additionally, the company collaborates with Aerpio Pharmaceuticals, Inc. regarding GB004 and related chemical entities. Founded in 2015, the enterprise was initially known as FSG, Bio, Inc. before rebranding as Gossamer Bio, Inc. in 2017. Its corporate headquarters are situated in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GOSS's potential to beat the market
- GOSS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GOSS
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.88 | A | |
| $52.10 | A | |
| $16.22 | A |
Be the first to know about important GOSS news, forecast changes, insider trades & much more!
GOSS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GOSS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GOSS ($0.17) is overvalued by 73.44% relative to our estimate of its Fair Value price of $0.10 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GOSS ($0.17) is not significantly undervalued (73.44%) relative to our estimate of its Fair Value price of $0.10 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GOSS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GOSS due diligence checks available for Premium users.
Valuation
GOSS fair value
Fair Value of GOSS stock based on Discounted Cash Flow (DCF)
Price
$0.17
Fair Value
$0.10
Overvalued by
75.50%
GOSS ($0.17) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GOSS ($0.17) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GOSS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GOSS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.21x
Industry
16.03x
Market
13.25x
GOSS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.24x
Industry
4.86x
GOSS's financial health
Profit margin
Revenue
$17.0M
Net Income
-$46.7M
Profit Margin
-275.2%
GOSS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
GOSS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$128.9M
Liabilities
$290.4M
Debt to equity
-1.8
GOSS's short-term assets ($124.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GOSS's long-term liabilities ($233.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GOSS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GOSS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$38.7M
Investing
$41.6M
Financing
$512.0k
GOSS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GOSS vs Biotech Stocks
Gossamer Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.